ESOU 2019: Debate: T2 Renal Tumors Best Surgical Treatment: Radical Nephrectomy

Prague, Czech Republic (UroToday.com) As part of the localized kidney cancer session, a debate discussing the optimal surgical treatment of T2 renal tumors. Dr. Peter Mulders from Radoudumc presented the position that the best treatment is radical nephrectomy.

ESOU 2019: Debate: T2 Renal Tumors Best Surgical Treatment: Partial Nephrectomy

Prague, Czech Republic (UroToday.com) As part of the localized kidney cancer session, a debate discussing the optimal surgical treatment of T2 renal tumors. Dr. Karim Bensalah from Rennes, France presented the position that the best treatment is partial nephrectomy.

ESOU 2019: Revolution in the First Line Treatment for Metastatic Renal Cell Carcinoma: Where Do We Stand?

Prague, Czech Republic (UroToday.com)  Dr. Peter Mulders presented at the close of the renal cell carcinoma section, focusing on metastatic renal cell carcinoma patients. He provided a review of the literature and some thoughts for the future.

ESOU 2019: Adjuvant Therapy after Nephrectomy for High Risk Renal Cell Carcinoma: The Oncologist's Perspective

Prague, Czech Republic (UroToday.com) Dr. Aristotelis Bamias approached the discussion of adjuvant therapy after nephrectomy for high-risk renal cell carcinoma (RCC) by providing the medical oncologists’ perspective – however, as he also noted, it is very similar to that of the urologists’ perspective, presented previously by Dr. Bex. He gave this same talk last year, at which time there were only 2 reported trials for adjuvant therapy for RCC – and at that time, his recommendation was against adjuvant therapy based on available data.

ESOU 2019: Cytoreductive Nephrectomy: What are the Current Recommendations?

Prague, Czech Republic (UroToday.com) Dr. Arnaud Méjean, the primary investigator and senior author the CARMENA study, was invited to review the current recommendations for cytoreductive nephrectomy. He had first presented the CARMENA results at ASCO 2018.

ESOU 2019: Adjuvant Therapy after Nephrectomy for High Risk Renal Cell Carcinoma: The Urologist's Perspective

Prague, Czech Republic (UroToday.com) Dr. Axel Bex approached the discussion of adjuvant therapy after nephrectomy for high-risk renal cell carcinoma (RCC) by providing the urologists’ perspective – however, as he noted, it is likely very similar to that of the medical oncologists’ perspective, presented by Dr. Bamias.

ESOU 2019: Best of Uro-Oncology 2018: Renal Cancer

Prague, Czech Republic (UroToday.com)  Dr. Bulent Akdogan presented the 2018 update on impactful papers in the field of renal cancer.

Localized Disease
The DISSRM prospective multi-institutional registry assessed growth kinetics of small renal masses on active surveillance among 271 patients with at least three follow-up images1.
Page 1 of 2
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe